Description: A Phase 1a/1b, Open-label, Multicenter Trial Investigating the
Safety, Tolerability, and Preliminary Anti-neoplastic Activity of S095029 (Anti-NKG2A) as Monotherapy and in Combination with Sym021 (Anti-PD-1) in Patients with Advanced Solid Tumor Malignancies followed by an Expansion Part with Triplet Combinations of S095029 and Sym021 and an Anti-HER2 mAb or Anti-EGFR mAbs (futuximab/modotuximab) in Patients with Metastatic Gastric or Colorectal Cancers
Target Population: In Monotherapy Dose Escalation. Patients receive 2 doses of S095029 then receive Sym021 (PD-1 Inhibitor) alone. Will move to combination and expansion cohorts.
Study Design: Study drug is administered IV every 2 weeks.